AstraZeneca to Delist from Nasdaq, Transition to NYSE Listing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: Benzinga
- Delisting Plan: AstraZeneca announced its voluntary delisting from Nasdaq, with trading ceasing on January 30, 2026, as part of a strategy to unify its global listing structure to attract a broader investor base.
- Listing Timeline: The company's ordinary shares and affected debt securities are expected to begin trading on the NYSE on February 2, 2026, allowing investors to trade across the London Stock Exchange, Nasdaq Stockholm, and NYSE.
- Cancer Drug Update: AstraZeneca's Enhertu has received validation for its marketing authorization application from the EMA, marking the start of the scientific review process and potentially offering new treatment options for HER2-positive breast cancer patients.
- Clinical Trial Results: In the DESTINY-Breast09 phase 3 trial, Enhertu in combination with pertuzumab demonstrated a statistically significant improvement in progression-free survival compared to traditional therapies, reinforcing its market potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
